Eliem Therapeutics | DEFA14A: Others
Eliem Therapeutics | DEFA14A: Others
Eliem Therapeutics | 8-K: Current report
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(44.3%),Peter Kolchinsky(44.3%), etc.
Eliem Therapeutics | ARS: Annual Report to Security Holders
Eliem Therapeutics | DEFM14A: Definitive proxy statement relating to merger or acquisition
Eliem Therapeutics | PREM14A: Preliminary proxy statements relating to merger or acquisition
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(45.3%),Peter Kolchinsky(45.3%), etc.
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Eliem Therapeutics | 10-Q: Quarterly report
Eliem Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Affinity Healthcare Fund, LP (EIN(6.02%),Affinity Asset Advisors, LLC (EIN(6.02%)
Eliem Therapeutics | 10-K/A: Annual report (Amendment)
Eliem Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(47.5%),Peter Kolchinsky(47.5%), etc.
Eliem Therapeutics | DEFA14A: Others
Eliem Therapeutics | 8-K: Current report
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Morisset Valerie
Eliem Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Eliem Therapeutics | 10-K: Annual report
Eliem Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pimblett Emily
Eliem Therapeutics | 8-K: Current report
No Data